Kevin Fitzgerald

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. ncbi request reprint RNAi versus small molecules: different mechanisms and specificities can lead to different outcomes
    Kevin Fitzgerald
    Bristol Myers Squibb Co, Department of Applied Genomics, Pharmaceutical Research Institute, P O Box 5400, Princeton, NJ 08534, USA
    Curr Opin Drug Discov Devel 8:557-66. 2005
  2. ncbi request reprint Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors
    Mark R Lackner
    Exelixis Inc, 170 Harbor Way, South San Francisco, California 94083, USA
    Cancer Cell 7:325-36. 2005
  3. pmc Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
    Maria Frank-Kamenetsky
    Alnylam Pharmaceuticals, 300 Third Street, Cambridge, MA 02142, USA
    Proc Natl Acad Sci U S A 105:11915-20. 2008

Collaborators

  • Muthiah Manoharan
  • Petra Ross-Macdonald
  • Maria Frank-Kamenetsky
  • Mark R Lackner
  • Birgit Bramlage
  • Norma N Anderson
  • Pamela Tan
  • David Butler
  • Christina Gamba-Vitalo
  • Jürgen Soutschek
  • Jamie Wong
  • Jay D Horton
  • Matthias John
  • Philipp Hadwiger
  • Hans Peter Vornlocher
  • Ingo Röhl
  • Akin Akinc
  • Daniel G Anderson
  • Timothy S Racie
  • Antonin de Fougerolles
  • Martin Maier
  • Muthusamy Jayaraman
  • Kallanthottathil G Rajeev
  • Lubomir Nechev
  • Yupeng Fan
  • Robert Langer
  • Gang Wang
  • Victor Koteliansky
  • Robert Dorkin
  • K Narayanannair Jayaprakash
  • Klaus Charisse
  • Timothy Read
  • Aldo Grefhorst
  • Tracy Zimmermann
  • Heshani de Silva
  • Michael R Cancilla
  • Dianne Parry
  • Yvonne Franke
  • Rachel M Kindt
  • Juan J Perez-Villar
  • Tim Heuer
  • Veeraswamy Manne
  • Mark Cockett
  • Michael Costa
  • Bo Guan
  • Greg Plowman
  • Katherine Brown
  • Pamela M Carroll
  • Changyou Chen
  • Carol O'Brien
  • Rajashekar K Reddy
  • Jae Moon Lee
  • Hong Xiao
  • Kevin Keegan
  • Hangjun Zhan
  • Tak Hung

Detail Information

Publications3

  1. ncbi request reprint RNAi versus small molecules: different mechanisms and specificities can lead to different outcomes
    Kevin Fitzgerald
    Bristol Myers Squibb Co, Department of Applied Genomics, Pharmaceutical Research Institute, P O Box 5400, Princeton, NJ 08534, USA
    Curr Opin Drug Discov Devel 8:557-66. 2005
    ..This review discusses the similarities, as well as the predicted differences between RNAi and small molecule effects on therapeutic paradigms and drug discovery...
  2. ncbi request reprint Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors
    Mark R Lackner
    Exelixis Inc, 170 Harbor Way, South San Francisco, California 94083, USA
    Cancer Cell 7:325-36. 2005
    ..These findings validate RabGGT, and by extension endosomal function, as a therapeutically relevant target for modulation of apoptosis, and enhance our understanding of the mechanism of action of FTIs...
  3. pmc Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
    Maria Frank-Kamenetsky
    Alnylam Pharmaceuticals, 300 Third Street, Cambridge, MA 02142, USA
    Proc Natl Acad Sci U S A 105:11915-20. 2008
    ..These results validate PCSK9 targeting with RNAi therapeutics as an approach to specifically lower LDLc, paving the way for the development of PCSK9-lowering agents as a future strategy for treatment of hypercholesterolemia...